JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis With KBI Biopharma, Inc.
JSR Life Sciences (JLS) announced today that JSR Corporation has agreed to acquire Selexis SA, a pioneering life sciences company and global leader in mammalian (suspension-adapted CHO-K1) cell-line generation technologies. Once completed, this transaction will mark the second major biotechnology addition to the JSR group of companies following JSR Corporation’s acquisition of KBI Biopharma in 2015. Selexis will be integrated within KBI Biopharma’s operations to create the most robust and fastest “Gene to GMP” service offering in the biopharmaceutical industry.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170614005189/en/
“Selexis has the best-in-class cell-line development technology and offers the ability to solve some of the most difficult expression challenges in biologics development,” said Eric R. Johnson, President of JSR’s Life Sciences Division. “JSR holds quality as the highest of its values and we see that same focus in Selexis. The Selexis technologies seamlessly integrate into the biologics development continuum, spanning discovery to commercialization. This allows us – in conjunction with KBI Biopharma – to move one step closer in our vision to become the biologics contract development and manufacturing organization (CDMO) of the 21st century.”
With biopharma’s ever-evolving pipeline of novel protein therapeutics, such as bi-specific antibodies, multimeric proteins and Fc-fusion proteins, CHO cells are being pushed to their productivity limits in drug development and manufacturing. Biopharmaceutical companies working on these promising new therapies are increasingly struggling with development challenges such as weak protein expression, low-yield purification steps, and poorly optimized analytical techniques. Without addressing these challenges, many of these new medicines capable of treating serious, intractable diseases would never advance out of the pre-clinical phase. Selexis has made its mark with its SUREtechnology Platform™ that facilitates the rapid, stable, and cost-effective generation of cell lines producing virtually any recombinant protein. KBI has a proven track record of delivering therapeutic candidates into the clinic by leveraging its strengths in process development and analytics. Moreover, KBI and Selexis already have a long history of successful collaboration on behalf of their partners, as KBI has performed development and/or manufacturing services using more than 15 different Selexis generated cell lines since 2012.
“Combining KBI’s robust analytical, process development, and reliable high-quality manufacturing capabilities with our Selexis SUREtechnology Platform, puts us in a position to offer current and future partners the ability to take their R&D programs from transfection to investigational new drug (IND) application in less than nine months,” said Igor Fisch, PhD, Selexis Chief Executive Officer. “By delivering the fastest timelines in the industry, our partners will benefit from substantial cost savings and patients will have access to critical drugs sooner. We believe in the ability of our combined technologies and knowhow to contribute to the medicines of tomorrow that will save the lives of those facing diseases as diverse as HIV and various cancers.”
“The combination of Selexis and KBI results in a truly unique opportunity to create value for our clients,” said KBI President Tim Kelly, PhD. “KBI and Selexis share the same mission and values based on innovation, scientific excellence, true partnership with our clients, and focus on the patients we serve. Together, Selexis and KBI represent the next generation CDMO for the biopharmaceutical industry, which will translate into more high-quality biologics entering the clinic faster.”
Terms of the sales and purchase agreement are not disclosed.
About JSR Life Sciences Division
JSR Life Sciences Division is a business unit of JSR Corporation, which provides specialized materials and products to the biotech industry. JSR Life Sciences operates a network of manufacturing facilities, sales offices and R&D labs in key markets throughout North America, Europe and Asia-Pacific. JSR Life Sciences is focused on diagnostics and research products and bioprocessing materials and services for the manufacture of biologics.
About Selexis SA
Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell-line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, more than 76 biologic drug development programs and three commercial products utilizing its cell lines, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.
About KBI Biopharma
KBI Biopharma, Inc. is a biopharmaceutical Contract Development and Manufacturing Organization that accelerates the development of innovative discoveries into life-changing biological products. From early-stage to academic/non-profit organizations, to many of the world’s largest pharmaceutical companies, KBI has served 250+ clients globally to accelerate and optimize their drug development programs.
KBI’s extensive track record of successful programs is a result of its unique approach: applying the insight gained from our advanced biophysical and analytical protein characterization techniques toward the development of robust and scalable processes. KBI delivers accelerated and integrated process development and cGMP manufacturing programs for a wide range of recombinant protein Active Pharmaceutical Ingredients (API) and cell therapy products for our clients. KBI was founded in 1996 and operates 4 facilities: Durham and Research Triangle Park (NC), Boulder (CO), and The Woodlands (TX).
Inquiries for JSR Life Sciences and KBI Biopharma, Inc.
Missy Bindseil, +1 830-237-9527
Media Inquiries for Selexis
Sam Brown Inc.
Mike Beyer, +1 312-961-2502
Company Inquiries for Selexis
Robert Meister, +1 602-953-1716
Head, Corporate Communications
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-30111.12.2017 09:30 | Tiedote
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-301 (camidanlumab tesirine or “Cami-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-301 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Hodgkin’s or non-Hodgkin’s lymphoma Dr. Steven M. Horwitz, Medical Oncologist at Memorial Sloan Kettering Cancer Center in New York City, and Principal Investigator, s
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 09:00 | Tiedote
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 08:01 | Tiedote
GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials11.12.2017 01:45 | Tiedote
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 18:30 | Tiedote
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 18:30 | Tiedote
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme